RadNet, Inc. RDNT
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
3/9
Piotroski F — financial health
1.28
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.0B | -$18.7M | — | — | $1.1B |
| 2024 | $1.8B | $2.8M | — | — | $1.1B |
| 2023 | $1.6B | $3.0M | — | — | $813.4M |
| 2022 | $1.4B | $10.7M | — | — | $491.5M |
| 2021 | $1.3B | $24.7M | — | — | $346.2M |
| 2020 | $1.1B | -$14.8M | — | — | $258.3M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.28 (grey)
- Working capital / assets 0.118
- Retained earnings / assets -0.025
- EBIT / assets 0.016
- Equity / liabilities 0.454
Source: SEC EDGAR filings · CIK 0000790526 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.